louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06974305: PET/MRI/EEG Imaging Study in Epilepsy
Official title: Investigation of Interictal Metabolic and Electrophysiologic Changes in Epilepsy Through Trimodal Neuroimaging
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Epilepsy
Keywords: Functional PET
FDG-PET
Functional MRI
EEG
Epilepsy
Neuroimaging
Multimodal imaging
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2025-05-15
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: Study populations are healthy people and people with epilepsy.

Brief summary: This study aims to better understand how epilepsy alters brain function through neuroimaging of healthy people and people with epilepsy. The study investigates how changes in brain metabolism (sugar consumption, measured by positron emission tomography \[FDG-PET\], and blood flow, measured by functional magnetic resonance imaging \[fMRI\]) relate to abnormal interictal electrical activity associated with epilepsy (measured by electroencephalography \[EEG\]). The study will also compare how the three imaging modalities localize regions of abnormal function in the brain.


Eligibility criteria: Inclusion Criteria:

* Age 18 or older

Additional Inclusion Criteria for Subjects with Epilepsy:

* Diagnosed with epilepsy with abnormal interictal EEG

Exclusion Criteria:

* Contraindications to PET, MRI, or EEG imaging
* History of severe brain disease such as stroke and head trauma
* History of brain surgery
* History of type I or II diabetes mellitus
* Fasting plasma glucose level \>200 mg/dL
* Employed under direct supervision of the PI conducting the research

Additional Exclusion Criteria for Healthy Subjects:

* Current use of drugs that modulate brain function
* Current or past history of major medical, neurological, or psychiatric conditions

Primary outcomes:
measure: Image analysis
timeFrame: Image analysis to be performed after imaging sessions are complete.
Secondary outcomes:
Other outcomes:
Locations:
city: Charlestown
country: United States
facility: Athinoula A. Martinos Center
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Ciprian Catana, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00372398: Premature Coronary Atherosclerosis in Scleroderma
Official title: Premature Coronary Atherosclerosis in Scleroderma: A Case Control Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Scleroderma
Keywords: scleroderma
sclerosis
atherosclerosis
Lead sponsor: Tuen Mun Hospital
Sponsor class: OTHER_GOV
First posted: 2006-09-06
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: scleroderma patients

Brief summary: The purpose of this trial is to study the proportion of scleroderma patients who suffer from asymptomatic coronary atherosclerosis compared to healthy controls.

Detailed description: Coronary calcium scores will be obtained from a group of patients with scleroderma and a group of controls. Comparison of the calcium scores will be made.

Eligibility criteria: Inclusion Criteria:

1. Age \>= 18 years.
2. Fulfillment of the American College of Rheumatology (ACR) criteria for the classification of scleroderma.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Tuen Mun Hospital
Study officials:
affiliation: Tuen Mun Hospital Hong Kong
name: CC Mok, MD FRCP
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01000298: Effectiveness of Oral Antibiotics in the Treatment of Severe Acute Malnutrition
Official title: Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effectiveness of Oral Antibiotics in the Community-based Treatment of Severe Acute Malnutrition in Malawian Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Kwashiorkor
Marasmus
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
First posted: 2009-10-23
Enrollment: 2700
Sex: ALL
Minimum age (years): 6
Maximum age (years): 5
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The need for oral antibiotics as part of the case management of severe acute malnutrition (SAM) in the outpatient setting has not been studied in a prospective trial. This study will compare the recovery rates of children with SAM treated at home with locally-produced ready-to-use therapeutic food (RUTF) with and without prescribed antibiotics as part of their outpatient case management. The investigators hypothesize that there will be no significant difference in rates of recovery between children who receive and children who do not receive antibiotics.


Eligibility criteria: Inclusion Criteria:

* 6 months - 5 years old
* Kwashiorkor or Marasmus
* Qualifies for home-based therapeutic feeding with RUTF

Exclusion Criteria:

* Obvious congenital or other malformation that makes child a poor candidate for home-based feeding with RUTF
* Unable to consume test-dose of RUTF in clinic
* Parent refusal to participate and return for follow-up

Primary outcomes:
measure: nutritional recovery
timeFrame: 12 weeks
Secondary outcomes:
measure: weight gain
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Blantyre
country: Malawi
facility: St. Louis Nutrition Project
Study officials:
affiliation: Washington University School of Medicine
name: Mark J. Manary, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Trehan I, Goldbach HS, LaGrone LN, Meuli GJ, Wang RJ, Maleta KM, Manary MJ. Antibiotics as part of the management of severe acute malnutrition. Malawi Med J. 2016 Sep;28(3):123-130.
citation: Trehan I, Goldbach HS, LaGrone LN, Meuli GJ, Wang RJ, Maleta KM, Manary MJ. Antibiotics as part of the management of severe acute malnutrition. N Engl J Med. 2013 Jan 31;368(5):425-35. doi: 10.1056/NEJMoa1202851.
Clinical trial NCT02292498: Thermal Imaging to Diagnose and Monitor Suspected Bacterial Infections
Official title: Thermal Imaging to Diagnose and Monitor Suspected Bacterial Infections
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infections, Bacterial
Pneumonia, Bacterial
Keywords: imaging, diagnostic
feasibility
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2014-11-17
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DEVICE_FEASIBILITY

Brief summary: The purpose of this study is to test the feasibility of using thermal images to diagnose bacterial pneumonia instead of a chest x-ray in the future. More specifically, the objectives of this study are: 1) to determine if thermal imaging, using a commercial thermal camera can detect areas of heat emitted from the chest in similar locations to where a chest X-ray shows focal consolidation consistent with bacterial pneumonia; 2) to evaluate whether changes in heat emitted from the chest changes over time if it is possible to obtain serial images of the chest.


Eligibility criteria: Inclusion Criteria:

* Subject sent for a clinical chest X-ray (not research) to rule out pneumonia
* Thermal images obtained using FLIR ONE within 4 hours of the chest x-ray
* Signed informed consent obtained
* Subject is a patient at a participating clinic at Massachusetts General Hospital

Exclusion Criteria:

* None

Primary outcomes:
measure: feasibility of diagnosis of bacterial pneumonia
timeFrame: 4 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Patricia L Hibberd, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05964998: Pilot Study of CBT With tDCS for Adults Being Treated for Obsessive Compulsive Disorder
Official title: Investigating Non-invasive Brain Stimulation to Enhance CBT in Intensive Treatment-seeking Patients With OCD
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Obsessive-Compulsive Disorder
Keywords: Obsessive-Compulsive Disorder
OCD
transcranial direct current stimulation
tDCS
Cognitive Behavior Therapy
CBT
Lead sponsor: Rogers Behavioral Health
Sponsor class: OTHER
First posted: 2023-07-28
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants randomized to either active tDCS stimulation or sham.
Primary purpose: TREATMENT

Brief summary: This pilot study aims to compare the effect of transcranial direct current stimulation (tDCS) versus sham stimulation, delivered immediately prior to cognitive-behavioral therapy (CBT) for obsessive-compulsive disorder (OCD), on patient-reported outcomes. The investigator hypothesize that patients who receive active stimulation will experience greater improvement in OCD symptoms than those who receive sham stimulation.


Eligibility criteria: Inclusion Criteria:

* Primary diagnosis of Obsessive-Compulsive Disorder (OCD)
* Resident of state of Wisconsin
* Enrolled in OCD Intensive Outpatient Program (IOP) at Rogers Behavioral Health in Oconomowoc, WI
* Ability to communicate effectively using written and spoken English

Exclusion Criteria:

* Metal in the body of any kind (e.g., braces, pacemakers, metal plates or screws, intracranial electrodes, implanted devices/defibrillators, prostheses)
* Currently taking medication that reduces seizure threshold (e.g., clomipramine)
* Cranial pathologies (e.g., holes, plates)
* History of seizure or black-out concussion
* Pregnancy
* Previous treatment at Rogers Behavioral Health

Primary outcomes:
measure: Change in Yale-Brown Obsessive-Compulsive Scale - Self-Report from admission to discharge
timeFrame: Up to 12 weeks
measure: Change in Quick Inventory of Depressive Symptomology from admission to discharge
timeFrame: Up to 12 weeks
Secondary outcomes:
measure: Number of treatment days between admission and discharge
timeFrame: Up to 12 weeks
measure: Change in Obsessive-Compulsive Inventory-Revised from admission to discharge
timeFrame: Up to 12 weeks
measure: Change in Quality of life enjoyment and satisfaction questionnaire - short form from admission to discharge
timeFrame: Up to 12 weeks
measure: Change in Intolerance of uncertainty scale from admission to discharge
timeFrame: Up to 12 weeks
measure: Change in Subjective units of distress from admission to discharge
timeFrame: Up to 12 weeks
Other outcomes:
Locations:
city: Oconomowoc
country: United States
facility: Rogers Behavioral Health
state: Wisconsin
Study officials:
affiliation: Rogers Behavioral Health
name: Bradley C Riemann, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00668798: Cytomegalovirus (CMV) Transmission by Frozen Breast Milk in Preterms
Official title: Incidence and Clinical Outcome of Human Cytomegalovirus Transmission Via Thawed Frozen Breast Milk in Preterm Infants <31 Weeks. A Prospective Trial.
Study type: OBSERVATIONAL
Overall status: SUSPENDED
Conditions: Cytomegalovirus
Keywords: cytomegalovirus breast milk preterm infants transmission
transmission of CMV via thawed frozen breast milk
Lead sponsor: Johann Wolfgang Goethe University Hospital
Sponsor class: OTHER
First posted: 2008-04-29
Enrollment: 58
Sex: ALL
Minimum age (years): 24
Maximum age (years): 31
Standard ages: CHILD
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: preterm infants of less than 32 weeks of gestation

Brief summary: Cytomegalovirus infection threatens preterm infant. We investigated, whether thawed breast milk is a mode of transmission

Detailed description: Preterm infants are at risk of symptomatic human cytomegalovirus infections transmitted by breast milk. This study evaluates incidence, timing, and clinical rlevance of acquired human CMV infections in preterm infants younger than 32 weeks of gestational age receiving maternal thawed frozen breast milk until 33 completed weeks of gestational age.

Eligibility criteria: Inclusion Criteria:

* preterm infants of less than 32 weeks of gestation

Exclusion Criteria:

* preterm infant of 32 weeks of gestational age or older, feeding with solely formula milk
* ourborn infants
* retroviral infection
* CMV status of mother unclear
* informed consent missing

Primary outcomes:
measure: CMV status of preterm infants
timeFrame: 2005-2008
Secondary outcomes:
measure: clinical manifestations of CMV infection
timeFrame: 2005-2008
Other outcomes:
Locations:
city: Frankfurt
country: Germany
facility: Childrens Hospital Goethe University
Study officials:
affiliation: Goethe University, Dpt of Neonatology
name: Karl Bauer, Professor
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hamprecht K, Maschmann J, Vochem M, Dietz K, Speer CP, Jahn G. Epidemiology of transmission of cytomegalovirus from mother to preterm infant by breastfeeding. Lancet. 2001 Feb 17;357(9255):513-8. doi: 10.1016/S0140-6736(00)04043-5.
Clinical trial NCT04355598: Cervical Lidocaine-Prilocaine Cream vs Glyceryl Trinitrate Cream in Nulliparous Women With LNG-IUD Insertion
Official title: Comparative Safety and Efficacy of Cervical Lidocaine-Prilocaine Cream Versus Glyceryl Trinitrate Cream on Pain Perception During Levonorgestrel- Intrauterine Device Insertion Among Nulliparous Women: a Randomized Double-blind Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Contraception
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2020-04-21
Enrollment: 195
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: the aim of the present study is to compare safety and efficacy of cervical Lidocaine-Prilocaine cream versus glyceryl trinitrate cream on pain perception during levonorgestrel- intrauterine device insertion among nulliparous women: a randomized double-blind controlled trial


Eligibility criteria: Inclusion Criteria:

* young and adolescent women requesting LNG-IUD insertion

Exclusion Criteria:

* parous women and contraindications to LNG-IUD placement or to the study drugs.

Primary outcomes:
measure: pain during LNG-IUD insertion
timeFrame: 5 minutes
Secondary outcomes:
measure: duration of the procedure
timeFrame: 10 minutes
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03836898: Presbyopic Phakic Intraocular Lens for Myopia Correction
Official title: Presbyopic Phakic Intraocular Lens for Myopia Correction
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Presbyopia
Myopia
Lead sponsor: Gemini Eye Clinic
Sponsor class: INDUSTRY
First posted: 2019-02-11
Enrollment: 10
Sex: ALL
Minimum age (years): 38
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a prospective single-center study of implantations of the presbyopic version of phakic intraocular lens IPCL (EyeolUK, United Kingdom).

Detailed description: Participants are impanted with the phakic intraocular lens IPCL (EyeolUK, United Kingdom) and monitored during 2 years period. Visual acuity for near and distance is evaluated, along with refraction and endothelium cell density.

Eligibility criteria: Inclusion Criteria:

* CDVA \< 0.3 LogMAR
* Presbyopia with moderate to high myopia
* Phakic

Exclusion Criteria:

* Corneal endotehleial cell density below 2000 cells/mm2
* Corneal dystrophies
* ACD less than 2.8 mm
* history or current uveitis
* acute ocular inflammation
* glaucoma
* chronic uveitis
* previous intraocular or refractive surgery
* preexisting ocular pathologic which may affect postoperative results

Primary outcomes:
measure: Change in Uncorrected Distance Visual Acuity (UDVA)
timeFrame: 2 years
measure: Change in Uncorrected Near Visual Acuity (UNVA)
timeFrame: 2 years
Secondary outcomes:
measure: Change in Corrected Distance Visual Acuity (CDVA)
timeFrame: 2 years
measure: Change in Corrected Near Visual Acuity (CNVA)
timeFrame: 2 years
measure: Change in distance refraction
timeFrame: 2 years
measure: Change in near refraction
timeFrame: 2 years
Other outcomes:
Locations:
city: Zlín
country: Czechia
facility: Gemini Eye Clinic
Study officials:
References:
citation: Stodulka P, Slovak M, Sramka M, Polisensky J, Liska K. Posterior chamber phakic intraocular lens for the correction of presbyopia in highly myopic patients. J Cataract Refract Surg. 2020 Jan;46(1):40-44. doi: 10.1097/j.jcrs.0000000000000033.
Clinical trial NCT02098798: Comparison of Surveillance Colonoscopy Techniques in Patients With IBD
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Inflammatory Bowel Disease
Keywords: Dysplasia, Inflammatory Bowel Disease
Lead sponsor: University of Calgary
Sponsor class: OTHER
First posted: 2014-03-28
Enrollment: 270
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Inflammatory bowel disease patients undergoing surveillance colonoscopy

Brief summary: We propose a randomized controlled study to determine the detection rates of neoplasia with high definition colonoscopy alone, high definition dye spraying chromoendoscopy or High definition iSCAN virtual chromoendoscopy in patients with long standing colitis (8 years from diagnosis except primary sclerosing cholangitis when surveillance starts at diagnosis) CD or UC.

We hypothesized that these novel endoscopic techniques using High definition colonoscopy with virtual chromoendoscopy -iScan 2 and 3 may be superior to high definition colonoscopy alone and similar to using dye spraying chromoendoscopy for detection of dysplasia and neoplasia in patients with long standing IBD.

We will aim to demonstrate if we can avoid dye spraying during the procedure and save expense and considerable time.

In addition, we can hope to produce evidence and inform the way in which we perform surveillance colonoscopy especially without large number of multiple random biopsies but only few targeted" smart and intelligent" biopsies using high definition colonoscopy with iSCAN technique as is already the European practice in several centres.


Eligibility criteria: Inclusion Criteria:

Clinical and histological diagnosis of UC or colonic CD-extensive or pancolitis.

UC -CD Disease duration 8 years from diagnosis UC-CD with associated primary sclerosing cholangitis from diagnosis Ulcerative Colitis Activity Index Mayo score 0-1 (inactive disease) Crohn's disease Activity Index - Harvey Bradshaw score \<4 (dysplasia detection requires quiescent inflammatory bowel disease)

Exclusion Criteria:

Known intraepithelial neoplasia or colorectal cancer or other neoplasia Coagulopathy which may prevent biopsies Pregnancy Inability to obtain informed consent

Primary outcomes:
measure: Detection of neoplasia in the 3 cohorts - high definition colonoscopy, HD colonoscopy + iSCAN, HD colonoscopy + dye chromoendoscopy
timeFrame: At the time of procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Calgary
country: Canada
facility: University of Calgary, Foothills Medical Centre
state: Alberta
Study officials:
References:
Clinical trial NCT01323998: Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan
Official title: Evaluating the Treatment Patterns in Men With Benign Prostatic Hypertrophy (Marketscan Database Study)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prostatic Hyperplasia
Keywords: enlarged prostate
Benign prostatic hyperplasia
alpha-blocker
5-alpha-reductase inhibitor
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2011-03-28
Enrollment: 35032
Sex: MALE
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Male patients aged 50 years or older with a diagnostic claim for BPH and at least one prescription claim for a 5ARI or AB in the enrollment period

Brief summary: This retrospective study aims to assess treatment patterns within 1 year of initiating BPH treatment, including 5-alpha-reductase inhibitor (5ARI) monotherapy, alpha-blocker (AB) monotherapy, early combination therapy, and delayed combination therapy. The MarketScan database will be utilized for this study (2000-2008)


Eligibility criteria: Inclusion Criteria:

* Male
* aged 50 years or older
* a diagnostic claim for BPH
* at least one prescription claim for a 5ARI or AB in the enrollment period
* continuous eligibility for 6 months prior to and 12 months after index prescription date

Exclusion Criteria:

* diagnosis of prostate or bladder cancer during the study period
* any prostate-related surgical procedure within 1 month of the index prescription date
* prescription claim for finasteride 1 mg for male pattern baldness during the study period

Primary outcomes:
measure: Number of Participants by Treatment Cohort With and Without a Benign Prostatic Hypertrophy (BPH) Diagnosis
timeFrame: 4 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
Clinical trial NCT00875498: Intermittent Theta Burst Stimulation (iTBS) for the Treatment of Negative Symptoms in Schizophrenia
Official title: Intermittent Theta Burst Stimulation (iTBS) for the Treatment of Negative Symptoms in Schizophrenia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Schizophrenia
Keywords: iTBS
Negative Symptoms
Lead sponsor: Hôpital le Vinatier
Sponsor class: OTHER
First posted: 2009-04-03
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether the iTBS is an effective treatment of the negative symptoms of schizophrenia.

Detailed description: This study will evaluate whether the intermittent Theta Burst Stimulation (iTBS), a new high frequency TMS protocol is efficient in the treatment of the Negative Symptoms of schizophrenia.

Neuroimaging studies demonstrate that hypoactivity in the left dorsolateral prefrontal cortex (LDLPFC) was associated with negative symptoms.

The investigators hypothesize that iTBS applied to LDLPFC will improve negative symptoms and will improve activity of the LDLPFC measured with Magnetic Resonance Spectroscopy (MRS).

Eligibility criteria: Inclusion Criteria:

* Schizophrenia according to DSM-IV
* Negative symptoms for at least 6 weeks
* Medication resistance according to Kane et al., 1988
* Age between 18 and 50 years old
* Informed consent

Exclusion Criteria:

* Contraindication to TMS
* Pregnancy

Primary outcomes:
measure: Scale for the Assessment of Negative Symptoms (SANS)
timeFrame: before, after 2 weeks of treatment, and 3 times follow-up (1, 3 and 6 months)
Secondary outcomes:
measure: Neurochemical impact of treatment measured by 1H-MRS, DTI and resting MRI
timeFrame: 3 times, before treatment, immediatly after treatment and a last evaluation 3 months after
Other outcomes:
Locations:
city: Bron
country: France
facility: Hopital Le vinatier
Study officials:
affiliation: Hopital Le Vinatier
name: Emmanuel Poulet, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hopital le Vinatier
name: JEROME BRUNELIN, PhD
role: STUDY_DIRECTOR
References: